Managers / Q2 2020 · view latest →
Burrage Capital Management LLC
CIK 0001796461 · 314 COMMONWEALTH AVENUE, #4, BOSTON, MA, 02115 · 617-410-4770
Summary
Burrage Capital Management LLC reported $143M in U.S.-listed holdings across 26 positions for Q2 2020.
Its largest position, Epizyme Inc Com, represents 10.0% of the portfolio.
Compared with Q1 2020, the fund opened 3 new positions and exited 8.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 84.3% · $120M
- Other · 15.6% · $22M
- ADR · 0.2% · $241,000
Quarter-over-Quarter Changes full breakdown →
vs Q1 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ADC THERAPEUTICS SA SHS ISIN#CH0499880968 | NEW | +134.9K | 134.9K | +$6M | $6M |
| FULCFULCRUM THERAPEUTICS INC COM | NEW | +291.6K | 291.6K | +$5M | $5M |
| MERUS B V COM ISIN#NL0011606264 | NEW | +140.2K | 140.2K | +$2M | $2M |
| AIMTAIMMUNE THERAPEUTICS INC COM | ADDED | +220.0K | 332.5K | +$4M | $6M |
| INSMINSMED INC COM PAR 01 | ADDED | +100.0K | 165.4K | +$4M | $5M |
| CTMXCYTOMX THERAPEUTICS INC | SOLD OUT | −483.0K | 0 | −$3M | $0 |
| CARA THERAPEUTICS INC | SOLD OUT | −258.8K | 0 | −$3M | $0 |
| TRICIDA INC | SOLD OUT | −131.7K | 0 | −$3M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2020
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $0 | 1 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $100M | 22 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $123M | 27 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $131M | 25 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $127M | 27 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $143M | 26 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $102M | 31 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $149M | 29 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.